LY 334370 hydrochloride
目录号 : GC12657A 5-HT1F receptor agonist
Cas No.:199673-74-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | in vitro studies, LY334370 is dissolved in buffer solution.--> Human cerebral artery is used in this study. Segments are prepared as previously described, but briefly they are placed in a buffer solution containing (mM) NaCl 119, NaHCo3 15, KCl 4.6, CaCl2 1.5, NaH2PO4 1.2, MgCl2 1.2, and glucose 5.5. Sections of vessel about 0.5 mm in diameter and 1 to 2 mm in length are mounted in a temperature-controlled tissue bath (37°C) containing buffer solution bubbled with 95% O2 and 5% CO2. The vessel segments are given a tension of 4 mN and allowed to stabilize at this tension for 1 to 1.5 h. Vessel reactivity is tested by exposure to 60 mM KCl. This is done twice for each segment and only if the response is similar to the segment used for LY334370 testing. Responses to LY334370 is calculated as a percentage of the maximum KC1 response[1]. |
Animal experiment: | in vivo studies, LY334370 is dissolved in 0.9% saline and is administered at a volume of 1 mL/kg except for hyperalgesia studies where it is dissolved in distilled water and is administered at a volume of 2 mL/kg.--> Male Sprague-Dawley rats (300 to 400 g) are anesthetized with pentobarbitone sodium. Briefly, a femoral artery and both femoral veins are cannulated for blood pressure recording, intravenous injection of drugs and infusion of anesthetic, respectively. Rats are placed in a stereotaxic frame, the skull exposed and thinned by drilling to reveal a branch of the middle meningeal artery whose diameter is measured continuously through the intact skull using intravital microscopy and a video dimension analyser. Neurogenic vasodilation is evoked using a bipolar stimulating electrode placed on the surface of the cranial window approximately 200 μM from the vessel of interest. A control vasodilation response to electrical stimulation is produced and 5 min later LY334370 (3 or 10 mg/kg, iv.) is given and the electrical stimulation repeated after a further 15 min. The mean maximum percentage increase in dural vessel diameter relative to pre-stimulus baseline is calculated for each response and comparisons of vasodilation responses evoked in the presence or absence of LY334370 are made by analysis of variance (ANOVA) followed by paired t-tests[1]. |
References: [1]. Shepheard S, et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia. 1999 Dec;19(10):851-8. |
LY334370 is a selective 5-HT1F receptor agonist with a Ki of 1.6 nM.
LY334370 has no vasoconstrictor effects on human cerebral arteries in vitro until a dose of 10-5 M, at which it produces a contraction of 8.5±5.7%; however, this is not significant[1].
Following intravenous administration of LY334370 at 3 mg/kg (n=3) or 10 mg/kg (n=6) electrical stimulation evokes an increase in dural blood vessel diameter of 135±6% and 106±11%, respectively, which is not significantly different from the respective control values. LY334370 has no effect on dural blood vessel diameter per se, since the actualdural blood vessel diameter is 43±4 arbitrary units before drug and 43±4 arbitrary units 15 min after injection of LY334370 (10 mg/kg)[1].
References:
[1]. Shepheard S, et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia. 1999 Dec;19(10):851-8.
Cas No. | 199673-74-0 | SDF | |
化学名 | 4-fluoro-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzamide hydrochloride | ||
Canonical SMILES | CN1CCC(C2=CNC3=C2C=C(NC(C4=CC=C(F)C=C4)=O)C=C3)CC1.Cl | ||
分子式 | C21H22FN3O.HCl | 分子量 | 387.88 |
溶解度 | <9.7mg/ml in Water; <9.7mg/ml in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.5781 mL | 12.8906 mL | 25.7812 mL |
5 mM | 0.5156 mL | 2.5781 mL | 5.1562 mL |
10 mM | 0.2578 mL | 1.2891 mL | 2.5781 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。